Literature DB >> 28446570

Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

B D Edwards1, J Greysson-Wong2, R Somayaji1, B Waddell2, F J Whelan3, D G Storey2,4, H R Rabin1,2, M G Surette2,5,3, M D Parkins6,2.   

Abstract

Achromobacter species are increasingly being detected in cystic fibrosis (CF) patients, with an unclear epidemiology and impact. We studied a cohort of patients attending a Canadian adult CF clinic who had positive sputum cultures for Achromobacter species in the period from 1984 to 2013. Infection was categorized as transient or persistent (≥50% positive cultures for 1 year). Those with persistent infection were matched 2:1 with age-, sex-, and time-matched controls without a history of Achromobacter infection, and mixed-effects models were used to assess pulmonary exacerbation (PEx) frequency and lung function decline. Isolates from a biobank were retrospectively assessed, identified to the species level by nrdA sequencing, and genotyped using pulsed-field gel electrophoresis (PFGE). Thirty-four patients (11% of those in our clinic), with a median age of 24 years (interquartile range [IQR], 20.3 to 29.8 years), developed Achromobacter infection. Ten patients (29%) developed persistent infection. Persistence did not denote permanence, as most patients ultimately cleared infection, often after years. Patients were more likely to experience PEx at incident isolation than at prior or subsequent visits (odds ratio [OR], 2.7 [95% confidence interval {CI}, 1.2 to 6.7]; P = 0.03). Following persistent infection, there was no difference in annual lung function decline (-1.08% [95% CI, -2.73 to 0.57%] versus -2.74% [95% CI, -4.02 to 1.46%]; P = 0.12) or the odds of PEx (OR, 1.21 [95% CI, 0.45 to 3.28]; P = 0.70). Differential virulence among Achromobacter species was not observed, and no cases of transmission occurred. We demonstrated that incident Achromobacter infection was associated with a greater risk of PEx; however, neither transient nor chronic infection was associated with a worsened long-term prognosis. Large, multicenter studies are needed to clarify the clinical impact, natural history, and transmissibility of Achromobacter.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Achromobacter xylosoxidans; emerging infections; epidemiology; eradication; infection control; infection transmission; inhaled corticosteroids; multilocus sequence typing; pulsed-field gel electrophoresis; whole-genome sequencing

Mesh:

Year:  2017        PMID: 28446570      PMCID: PMC5483909          DOI: 10.1128/JCM.02556-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  55 in total

1.  Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.

Authors:  Sabine Van Daele; Rita Verhelst; Geert Claeys; Gerda Verschraegen; Hilde Franckx; Leen Van Simaey; Catharine de Ganck; Frans De Baets; Mario Vaneechoutte
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

Review 2.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.

Authors:  J W Krzewinski; C D Nguyen; J M Foster; J L Burns
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 4.  Pseudomonas aeruginosa and Burkholderia cepacia in cystic fibrosis: genome evolution, interactions and adaptation.

Authors:  Leo Eberl; Burkhard Tümmler
Journal:  Int J Med Microbiol       Date:  2004-09       Impact factor: 3.473

5.  Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.

Authors:  J K Block; K L Vandemheen; E Tullis; D Fergusson; S Doucette; D Haase; Y Berthiaume; N Brown; P Wilcox; P Bye; S Bell; M Noseworthy; L Pedder; A Freitag; N Paterson; S D Aaron
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

6.  Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK.

Authors:  Amy Coward; Dervla T D Kenna; Claire Perry; Kate Martin; Michel Doumith; Jane F Turton
Journal:  J Cyst Fibros       Date:  2015-09-26       Impact factor: 5.482

7.  Alcaligenes infection in cystic fibrosis.

Authors:  Kenneth Tan; Steven P Conway; Keith G Brownlee; Christine Etherington; Daniel G Peckham
Journal:  Pediatr Pulmonol       Date:  2002-08

8.  Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone.

Authors:  M Kanellopoulou; S Pournaras; H Iglezos; N Skarmoutsou; E Papafrangas; A N Maniatis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

9.  Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.

Authors:  Lucie Amoureux; Julien Bador; Eliane Siebor; Nathalie Taillefumier; Annlyse Fanton; Catherine Neuwirth
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

10.  The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.

Authors:  Kay A Ramsay; Harpreet Sandhu; James B Geake; Emma Ballard; Peter O'Rourke; Claire E Wainwright; David W Reid; Timothy J Kidd; Scott C Bell
Journal:  J Cyst Fibros       Date:  2016-08-08       Impact factor: 5.482

View more
  24 in total

1.  Achromobacter xylosoxidans Cellular Pathology Is Correlated with Activation of a Type III Secretion System.

Authors:  Adam M Pickrum; Orlando DeLeon; Aaron Dirck; Maxx H Tessmer; Molly O Riegert; Julie A Biller; Nathan A Ledeboer; John R Kirby; Dara W Frank
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

Review 2.  Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory.

Authors:  Deirdre L Church; Lorenzo Cerutti; Antoine Gürtler; Thomas Griener; Adrian Zelazny; Stefan Emler
Journal:  Clin Microbiol Rev       Date:  2020-09-09       Impact factor: 26.132

3.  Distribution of Achromobacter Species in 12 French Cystic Fibrosis Centers in 2020 by a Retrospective MALDI-TOF MS Spectrum Analysis.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Anaïs Folletet; Julien Bador; Maryam Abid; Marlène Amara; Clémence Beauruelle; Olivier Belmonte; Pierre Boyer; Emilie Cardot-Martin; Anne-Gaëlle Cauchie; Sylvie Colin de Verdière; Claire Daurel; Cécile Gaudru; Farida Hamdad; Geneviève Héry-Arnaud; Baptiste Hoellinger; Claudie Lamoureux; Marie-Frédérique Lartigue; Damasie Malandain; Océane Marchand; Caroline Piau; Sandrine Picot; Hélène Revillet; Zeina Sabouni; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2022-05-05       Impact factor: 11.677

4.  Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Achromobacter Species from Cystic Fibrosis Patients.

Authors:  Ijeoma N Okoliegbe; Karolin Hijazi; Kim Cooper; Corinne Ironside; Ian M Gould
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 5.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

6.  A chromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis.

Authors:  Charlotte Marsac; Laura Berdah; Guillaume Thouvenin; Isabelle Sermet-Gaudelus; Harriet Corvol
Journal:  ERJ Open Res       Date:  2021-05-31

7.  Analysis of a Novel Bacteriophage vB_AchrS_AchV4 Highlights the Diversity of Achromobacter Viruses.

Authors:  Laura Kaliniene; Algirdas Noreika; Algirdas Kaupinis; Mindaugas Valius; Edvinas Jurgelaitis; Justas Lazutka; Rita Meškienė; Rolandas Meškys
Journal:  Viruses       Date:  2021-02-27       Impact factor: 5.048

8.  Duplex real-time PCR assay for the simultaneous detection of Achromobacter xylosoxidans and Achromobacter spp.

Authors:  Erin P Price; Valentina Soler Arango; Timothy J Kidd; Tamieka A Fraser; Thuy-Khanh Nguyen; Scott C Bell; Derek S Sarovich
Journal:  Microb Genom       Date:  2020-07-15

9.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Rapid Detection of Isolates Belonging to the Epidemic Clones Achromobacter xylosoxidans ST137 and Achromobacter ruhlandii DES from Cystic Fibrosis Patients.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Angélique Chapuis; Véronique Varin; Julien Bador; Nadia Makki; Lise Cremet; Elise Persyn; Emilie Cardot-Martin; Fedoua Echahidi; Charlotte Peeters; Denis Pierard; Peter Vandamme; Alexia Verroken; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2021-08-04       Impact factor: 5.948

10.  Does the human placenta delivered at term have a microbiota? Results of cultivation, quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics.

Authors:  Kevin R Theis; Roberto Romero; Andrew D Winters; Jonathan M Greenberg; Nardhy Gomez-Lopez; Ali Alhousseini; Janine Bieda; Eli Maymon; Percy Pacora; Jennifer M Fettweis; Gregory A Buck; Kimberly K Jefferson; Jerome F Strauss; Offer Erez; Sonia S Hassan
Journal:  Am J Obstet Gynecol       Date:  2019-03       Impact factor: 10.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.